The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 07, 2016

Filed:

Apr. 10, 2015
Applicant:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, CN;

Inventors:

Hong Liu, Shanghai, CN;

Xin Xie, Shanghai, CN;

Xuechu Zhen, Shanghai, CN;

Haifeng Sun, Shanghai, CN;

Jing Li, Shanghai, CN;

Liyuan Zhu, Shanghai, CN;

Zeng Li, Shanghai, CN;

Ying Chen, Shanghai, CN;

Hualiang Jiang, Shanghai, CN;

Kaixian Chen, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4741 (2006.01); C07D 491/12 (2006.01); C07D 491/153 (2006.01); C07D 455/03 (2006.01); C07D 491/147 (2006.01); C07D 491/22 (2006.01); C07C 69/736 (2006.01); C07C 231/14 (2006.01); C07D 217/20 (2006.01); C07D 311/20 (2006.01); C07D 491/056 (2006.01);
U.S. Cl.
CPC ...
C07D 491/153 (2013.01); C07C 69/736 (2013.01); C07C 231/14 (2013.01); C07D 217/20 (2013.01); C07D 311/20 (2013.01); C07D 455/03 (2013.01); C07D 491/056 (2013.01); C07D 491/147 (2013.01); C07D 491/22 (2013.01);
Abstract

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.


Find Patent Forward Citations

Loading…